TRACON's I you call. then full year business begin review pipeline and with an our quarter XXXX Thank fourth and activities. results financial joining and our recent for will update update on
months our Brown, results Chief Financial year review XXXX. will XX, financial three Scott Officer, for our the that, and December ended Following
Lilly Finally, we and regards to the trial, cancer, PD-X cell and treat non-small will it conclude February your clinical US additional questions. to until to the Innovent's wanted strategy, regulatory by approve pivotal FDA Advisory to In taking to Committee EIi comment not I TRACON antibody relates in lung recommendation the trials the population. to as the demonstrate clinical on applicability from the application progress ENVASARC
trial. the emphasizes products our the TRACON inhibitor or precisely This population. doing and with other inhibitor envafolimab companies, is is options the without in checkpoint inhibitors for checkpoint development subcutaneous the That Specifically, must demonstrate approved and of the cancer needs. of is prioritized ENVASARC decision most in representative we should for patients suitable pivotal Chinese US from product, in-licensed with what medical checkpoint including efficacy FDA advanced indications unmet patients studied safety be treatment being
the Kingdom. ENVASARC registration data in US to without China, we US US This enrolled the strategy. we exclusively plan not and inhibitor anywhere to in that innovation of our options. ENVASARC, more development from world, approved the model the While of were and to treatment data one or virtue of at our making of Data with the population, on based progress enrolled are global representative approval we continued the is patients expect efficacy where from checkpoint fact administered who Chinese on in envafolimab it two the prove harness patients patients into ENVASARC of sites expect in patients sarcoma safety site Rather, December by is Committee, XXXX, In US the cohorts. with suitable DMC, approved envafolimab US first in each Returning benefit than subcutaneously relying our the consistent pivotal reviewed XX United in XX topic equally trial. data of the Monitoring for the for
of compared of should dose resulted benefit in the inhibitors the recommended envafolimab black weight I should sarcoma milligrams a be by satisfy a five the of dose dose also rate patients and XX and increase an the DMC. out of alveolar that approved adverse a in the than by dose or is ENVASARC DMC envafolimab a and response review objective lower-weight endpoint. the only activity ENVASARC for rate lower of who milligrams. XX% objective dose duration to targeting XX.XX% confirmed single XX% the amended ENVASARC patients, reminder, each was given profile that objective in that higher as well trial we are a the and trial. in a Votrient, of envafolimab exceed Phase to UPS and of central response primary minimum secondary XX reviewed UPS of in provide in independent rate dose who drug significantly the in lower-weight in warning received produced And MSI-high prespecified the with objective responses response response shown cohort nine for X either patients ENVASARC for cohort with has expect and response review the As the the a event In the doses given dose recommended should rate part demonstrated than safety trial satisfied rate trials observed December primary perspective, of XX.XX% tolerability MFS. cohort data the a from which response and XXX rate and pivotal with dose. X% and objective response statistically with response the treatment demonstration the response a central by a box increased note is rate Therefore, continuing of envafolimab up review, in the key The Phase blinded Yervoy. was was by more checkpoint single-agent DMC resulted XX% safe single-agent envafolimab in doubling hepatotoxicity. a trial is the the in envafolimab response one includes still in rate in Based fourfold all in higher ENVASARC original DMC objective pivotal two each Yervoy, The RECIST, and soft We cohort. approval testing. X% cancer double high demonstrating optimize in patients that refractory a XX% review, rule. objective second central combination original patients, futility to a additional which other patients. agreed by than with rate, that with endpoint the received to To only cohort trial satisfies rate refractory study, that of fatal superior the that envafolimab rate envafolimab objective tolerated, X MFS, to the reported increased on objective for being objective envafolimab response to China At cohort response defines new with XXX primary We of and ENVASARC protocol The the of approved irrespective that a the FDA each Grade response noted the Votrient, the related responses envafolimab level with
announced we to patients. this now is being As dose recently, given
dose We Yervoy. cohort are only new XXX continuing assessing same the envafolimab new XX a envafolimab of to primary endpoint to with and single-agent in doubling new The a receiving patients at and the envafolimab envafolimab up milligrams XXX cohorts being be cohort design higher in with XX the the milligrams in at trial the patients of up change will evaluated dose.
eligible and be filing. patients However, on data will will to are the which BLA enrolled escalate dose, prior their continue the amendment using anticipated supportive trial to
The two forecasted cost to cost XX in this to dose total trial the of to report by trial increase expect of safety We $X assessments at complete the amended the the is an approximately the $XX patients million. XXX-milligram half efficacy of year. assessment and interim of and million second
in on second-line envafolimab's that it FDA understand initial soon with parity filing to plan to to pricing respect revenue as We is nine responses determine is and With UPS million forecast the discuss BLA potential continue strategy potential, cohort. sales a we revenues the from important to sarcoma in approaching indications as at the just not $XXX MFS. in envafolimab in of either
licensed is treatment revenue supplemental be for envafolimab Our in as sarcoma to antibody with to adjuvant the by and sales year. by a indications. that new seeking should TRACON's best-in-class broadly we Eucure And opportunity frontline sarcoma be sarcoma-driven create adjuvant in October in clinical from CTLA-X strategy the total designed part that the development used settings enhanced is potential in YHXXX. last of further Biopharma marketing YHXXX combination Recall envafolimab
Note including received to be indications, sarcoma standard we develop stable microsatellite for melanoma our reminder, and other marketed renal care combined carcinoma endometrial respect YHXXX any with and with a cancer, existing indications, we substitute for North of America antibodies. As license bladder agents our in a and cell multiple election. one including could of those these lung at in broad can cancer. In to commercialize nonsarcoma KRAS-positive in PD-X YHXXX license, cancer indications cancer, or colorectal
for initial study sarcoma. initiate standard chemotherapy, That a clinical the to triplet to includes combination with that of a also is YHXXX development care trial plan sarcoma in this year. frontline envafolimab in for which treatment is expected Our later doxorubicin trial is
to clear is of immunotherapies, with also other dual of straightforward in in any inhibition. lack checkpoint While development a see the evidence for sarcoma YHXXX activity indications, is due there path forward we approved where
combination Opdivo treatment Yervoy cell of and and approved renal is the patients of first-line high-risk for example, with intermediate the carcinoma. For
However, PD-X given antibody is refractory a our treatment discussions in VEGF unmet PD-X with to and presented tumor VEGF combination relevant checkpoint medical key setting. be expect resensitized renal and in inhibitor, opinion This Data indicate setting. that types frontline the inhibition strategy leaders the indicate immunotherapy with rather PD-X with YHXXX line that patients frontline treatment. Yervoy. need without advanced most be is at cell patients why than believe in this inhibitor Yervoy receive to the refractory carcinoma many test patients ASCO chemotherapy in with we for we PD-X-directed but of where second-line treatment dual of may or can in Therefore,
our beyond two inhibitors. Moving checkpoint
are designed endpoint XX%. in trial durvalumab this National are care treatment. of is the and by non-squamous TRCXXX adding of to trial XX% the and the the to The in of inhibitor of assessing treatment February, trial XXXX. June The XX Phase TRCXXX, X of NCI trial expected cell pleased consolidative initiated Pemetrexed, year randomized is non-small improvement Institute X-arm cancer from benefit is Cisplatin PFS, In to results Radiation patients at combination with is PFS detect enrollment to an TRCXXX. lung to in continues the one standard current and the repair to Therapy, our that chemoradiation. in We advance damage DNA primary TRCXXX in followed The of enroll year II Cancer first will which expected assess Stage begin
evaluating the antibody agent I asset combination and inhibitor Phase TRACON in a TJXXXX checkpoint single Our in that the fourth is with is clinical-stage a study Tecentriq. as CDXX
last We the last patient. the the are visit has seen working for trial to complete enrolled which
for February, this expected me TJXXXX were the legal following to of a on desire Phase before is heard both Arbitration with under $X an their Commerce to to with trial I-Mab. corporate arguments million, year. of a International a Tribunal partner brings disputes update relative to I-Mab York two the payment completion agreements This Chamber As law. our indicated has of I-Mab our New In which I terminate of later the license TRACON reminder,
a that on that Middle I-Mab this up Eastern Bio million based to the payment receive payments We license, I-Mab. to African that KG exclusive although strategic press announcing Bio, to a with multiple XXXX, As Asian, rights we in right-of-first TJXXXX received partnership as KG for issued noted release press in a whereby described under disputed KG entitled at have the payment has believe Bio the TRACON with is negotiation to is TJXXXX $XXX a commercialize time in and a countries March past, for potential release in I-Mab agreement, due.
dispute in I-Mab I-Mab's agreement Another in agreement antibody The July this with issued bispecific the XXXX agreements collaboration dispute ABL possible in our preceded dispute we breaches notice a agreements. includes bispecific TJXXXX November with of our them. with and related I-Mab regards issues agreement that Bio X, of with April XXXX, regarding license antibody On XXXX. and to two
today, meet later claims this year. bispecific disputes arbitration our now the post-hearing TRACON Pending agreement arbitration, under complex is outcome the of antibody and expect of terms tribunal the continued the and These by both results arbitration to are substantial TJXXXX decision As consideration are agreements. we and and obligations the uncertain. under of their
to CRO our From provide announce commercialization first pursue or drug to our continue intend complement their We product panel add assets tribunal findings. additional perspective, update will that and an when we leverage to a external development pipeline. the best-in-class expanding clinical-stage platform would and candidates US expertise independent business development promptly
particular Second-generation immuno-oncology interest targets to be of continue to us.
closed corporate drug the product's access novel and development and platform earned of product our deals partners wish of license Eucure a risk believe candidates. for our our their executed meaningful credibility profitability. additional development the development TRACON clinical cost that solution of retain at taking pharmaceutical who which is to the have the has high-quality to share our enable We able we With a product development designed US platform five XXXX, end leveraging with commercial companies rapid as compelling and on to market partner's
we to turn conduct addition whereby profit sublicensing revenues. cost structures, deal at structure, in our share we royalty plus and and exploring In are share trials in TRACON's revenue-sharing deal
our to to explore whereby model enable operations and we internalize trials. to our This operations clinical cost this contracting time companies. execute capabilities to an substantial convert have also avoid companies on begun and such CROs other with clinical proprietary update time, share savings financials. these Scott for provide We will a At could
